SageView Advisory Group
RXRX icon

SageView Advisory Group’s Recursion Pharmaceuticals RXRX Stock Holding History

SageView Advisory Group’s Portfolio RXRX Stock Details RXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,000
Closed -$4.09K – 2061
2025
Q4 		$4.09K Buy
+1,000
New +$4.95K ﹤0.01% 2025

Other funds holding RXRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SoftBank Group
SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
MCMU
MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

SageView Advisory Group's RXRX Position: Q1 2026 in Review

SageView Advisory Group sold out of Recursion Pharmaceuticals (RXRX) in Q1 2026, closing a stake of 1,000 shares — an estimated $4.09K sold.

SageView Advisory Group first reported a position in RXRX in Q4 2025 and held it in 1 quarter. The position peaked at $4.09K in Q4 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

  • SageView Advisory Group reported no remaining Recursion Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • SageView Advisory Group sold 1,000 Recursion Pharmaceuticals shares in Q1 2026, an estimated $4.09K.
  • SageView Advisory Group first reported a position in Recursion Pharmaceuticals in Q4 2025 and held it in 1 quarter.
  • SageView Advisory Group's Recursion Pharmaceuticals position peaked at $4.09K in Q4 2025.
  • 335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on SageView Advisory Group's 13F filing for Q1 2026, filed 10 Aug 2026.